EVALUATION OF THE EFFECTIVENESS OF VIRUS REMOVAL DURING THE PURIFICATION OF IMMUNOGLOBULIN G BY CHROMATOGRAPHY

DOI: https://doi.org/10.29296/25877313-2019-09-05
Issue: 
9
Year: 
2019

N.V. Zubkova Dr.Sc. (Pharm.), Deputy Head of Technology of R&D Department; Joint Stock Company «Microgen Scientific Industrial Company for Immunobiological Medicines» (Moscow) E-mail: n.v.zubkova@microgen.ru M.M. Kuznetsova Technologist, Diagnostic Department; Branch of Joint Stock Company «Microgen Scientific Industrial Company for Immunobiological Medicines» Nizhny Novgorod (Nizhny Novgorod) E-mail: m.m.kuznetsova@microgen.ru A.V. Ivanov Ph.D. (Pharm.), Leading Research Scientist, Branch of Joint Stock Company «Microgen Scientific Industrial Company for Immunobiological Medicines» Perm «Biomed» (Perm) E-mail: Ivanoffal@yandex.ru E.V. Filatova Ph.D. (Biol.), Head of R&D Division; Branch of Joint Stock Company «Microgen Scientific Industrial Company for Immunobiological Medicines» Nizhny Novgorod «ImBio» (Nizhny Novgorod) E-mail: hbsantigen@yandex.ru E.V. Orlova Dr.Sc. (Pharm.), Director; Joint Stock Company «Microgen Scientific Industrial Company for Immunobiological Medicines» Perm «Biomed» (Perm) E-mail: e.v.orlova@microgen.ru A.M. Nikolaeva Dr.Sc. (Biol.), Head of R&D Division; Branch Joint Stock Company «Microgen Scientific Industrial Company for Immunobiological Medicines» Perm «Biomed» (Perm) E-mail: a.m.nikolaeva@microgen.ru S.M. Staroverov Dr.Sc. (Chem.), General director; Closed Joint-Stock Company «BioChemMack ST» (Moscow) E-mail: info@bcmst.ru V.S. Karasev Ph.D. (Biol.), Leading Research Scientist, Closed Joint-Stock Company «BioChemMack ST» (Moscow) E-mail: karasev@bcmst.ru

Introduction. An innovative manufacturing process was developed to produce the highly purified preparation BioGam® “Human Immuno-globulin Normal, solution for infusion, 50 mg / ml, 100 mg / ml” using a combination of ethanol fractionation and chromatography on ion exchange and hydrophobic resin and an additional virus inactivation steps to achieve a reliable level of preparation safety. Aim. This study aimed to investigate the nucleic acids (NA) clearance efficacy of the hepatitis B (HBV), hepatitis C viruses (HCV) and parvovirus B19 (B19 V) during chromatography process for the isolation and purification of immunoglobulin G from precipitate A (Cohn fraction II + III). Materials and methods. Investigations were performed in model experiments with 3 series of precipitate A (II+III) samples knowingly con-taminated with a virus containing material in which NA concentration of HBV virus was (1.77 ± 0.42) · 104 IU / ml, HCV virus was (1.42 ± 0.14) · 103 IU / ml, B19V virus (1.82 ± 0.14) · 105 IU / ml and which were exposed to chromatographic separation on the scale-down model of the manufacturing process. The virus reduction factor was determined by the change in viral load in product fractions before and after the chromatography process. Results. It has been established that the chromatography process demonstrated a reliable and reproducible level of virus nucleic acids reduc-tion including to an undetectable by PCA level providing a reduction factor for HBV (3.61 ± 0.11) lg, for HCV (2.23 + 0.03) lg and for B19V (3.77 ± 0.02) lg. Conclusion. А chromatographic stage in the manufacturing process of preparation BioGam® makes a significant contribution to ensuring its vi-ral safety wherein the removal efficiency of blood-transmissible agents has been confirmed experimentally.

Keywords: 
immunoglobulin G
chromatography
scale-down model of manufacturing process
viral reduction
blood preparations

References: 
  1. WHO Guidance document on viral inactivation and removal procedure intended to assure the viral safety of blood plasma products. WHO Technical Report, Series № 924, Annex 4 (2004). Available at: http//www.who.int/bloodpro¬ducts/pub¬lica¬tion/en/.
  2. Gröner A. Pathogen safety of plasma-derived products  Haemate P/Humate-P. Haemophilia. 2008; 14 (5):5471. DOI: https://doi.org/10.1111/j.1365-2516.2008.01852.x.
  3. Velthove K.J., Over J., Abbink K., Janssen M.P. Viral safety of human plasma-derived medicinal products: impact of regulation requirements. Transfus. Med. Rev. 2013; 27 (3): 179183. DOI: https://doi.org/10.1016/j.tmrv.2013.05.002.
  4. Laursen I.A., Blou L., Sullivan J.S., Bang P., Balstrup F., Houen G. Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma. Transfus. Med. Hemother. 2014; 41(3): 205212. DOI: https://doi.org/10.1159/000357982.
  5. Radomski K.U., Lattner G., Schmidt T., Römisch J. Pathogen safety of a new intravenous immune globulin 10% liquid. BioDrugs. 2017; 31(2): 125-134. DOI: http://dx.doi.org/10.1007/s40259-017-0212-y.
  6. Patent 2467783 (RF). Sposob polucheniya immunoglobulinov iz frakcij, kotorye obrazuyutsya pri frakcionirovanii chelovecheskoj plazmy krovi [Elektronnyj resurs] / V.S. Karasev, O.P. Bochkova, S.M. Staroverov, I.V. Krasil'nikov, A.M. Nikolaeva, V.P. Petrovskih, A.B. Perevozchikov; zayavl. 30.07.2010; opubl. 10.12.2012. Rezhim dostupa: //http://www.findpatent.ru/pa¬tent/246/2467783.html
  7. Roberts P.L., Dunkerley C., Walker C. Virus reduction in an intravenous immunoglobulin by solvent/detergent treat-
  8. ment, ion-exchange chromatography and terminal low pH incubation. Biologicals. 2012; 40(5):345352. DOI: https://doi.org/10.1016/j.bio¬lo¬gicals.2012.04.007
  9. Virus validation studies: the design contribution and inter-pretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95 (1996). Available at: https://www.ema.europa.eu/virus-validation-studies-design-contribution-interpretation-studies-validating-inactivation-removal.
  10. Pravila provedeniya issledovanij biologicheskih lekarstvennyh sredstv Evrazijskogo ekonomicheskogo soyuza. Utv. Resheniem Vysshego Evrazijskogo ekonomich-eskogo soveta ot 03.11.2016. Available at: http://docs.cntd.ru/docu¬ment/456026116.
  11. Pravila nadlezhashchej proizvodstvennoj praktiki. Utv. prikazom №916 Minpromtorga Rossii ot 14.06.2013. Available at: http://www.consultant.ru/docu-ment/cons_doc_LAW_152004/.
  12. Utv. prikazom №916 Minpromtorga Rossii ot 14.06.2013. Available at: http://www.consultant.ru/docu-ment/cons_doc_LAW_152004/.